Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 215

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 215
---
 Compensation Actually Paid to Non-PEO NEOs (2) (e) Total Shareholder Return (3)(f) Peer Group Total Shareholder Return (4)(g) Net Loss (5) (h) Company Selected Measure (6)(i) 2024 $12,423,473 ($5,232,848) $3,493,347 $2,614,573 $31 $94 ($599,493) $ — 2023 $9,918,093 ($2,160,939) $3,143,102 $2,298,902 $62 $49 ($205,275) $ — 2022 $12,031,969 ($40,073,641) $4,133,800 ($386,119) $77 $67 ($176,063) $ — 2021 $24,703,855 $69,061,855 $3,324,746 $6,080,786 $145 $116 ($140,848) $ — (1) The dollar amounts reported are the amounts reported for Christopher Anzalone (the Company’s Chief Executive Officer) for each of the corresponding years in the “Total” column in our Summary Compensation Table. The dollar amounts reported in column (d) represent the average of the amounts reported for the Company’s named executive officers (NEOs) as a group (excluding Christopher Anzalone) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs included for these purposes in each applicable year are as follows: (i) for fiscal year 2024, Kenneth Myszkowski, Patrick O'Brien, James Hamilton, Javier San Martin and Tracie Oliver, (ii) for fiscal year 2023, Kenneth Myszkowski, Patrick O'Brien, James Hamilton, and Javier San Martin; (iii) for fiscal year 2022, Kenneth Myszkowski, Patrick O'Brien, James Hamilton, and Tracie Oliver; and (iv) for fiscal year 2021, Kenneth Myszkowski, Patrick O'Brien, James Hamilton, Javier San Martin, and James Hassard. (2) The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Christopher Anzalone, and the dollar amounts reported in column (e) represent the average amount of “compensation actually paid” to our other NEOs as a group, each as computed in accordance with Item 402(v) of Regulation